Skip Navigation

JNCI Journal of the National Cancer Institute 1998 90(18):1324-1326; doi:10.1093/jnci/90.18.1324
© 1998 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Reh, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Reh, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Biotechnology Industry Roars Into The Millennium

Nearly three decades after two California scientists pioneered recombinant DNA technology, biomedical research is undergoing explosive growth, and the industry fueling that growth is poised to break even financially for the first time ever.

Over the last year, the biotechnology industry in the United States has seen a 20% jump in product sales, setting a new industry record. This milestone is due in large part to the accelerated pace at which biologics have gained marketing approval in recent years: almost as many biologically based drugs and devices were approved by the Food and Drug Administration in 1997 as were approved in the entire decade of the 1980s.


"We are on the brink of a revolution in medicine," summed up David G. Nance, president and chief executive officer of Introgen Therapeutics, Inc., in Austin, Texas. "The medicines used to treat our parents and keep them . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?